Cellular mediators like cytokines that are released as a reaction to cell injury or excessive stimulation can lead to the synthesis of chemotactic eicosanoid leukotriene B4 (LTB4) among others. This mediator acts as a potent chemokine promoting migration of macrophages and neutrophils into tissues during inflammation. Researchers from CNRS, Universitat de Barcelona and colleagues reported the synthesis and evaluation of new 1,4-benzodioxine derivatives with selective LTB4 antagonism activity that led to the identification of [I] as the lead compound, which had higher affinity for LTB4 receptor with an IC50 value of 288 nM.
Huchembio Co. Ltd. has described signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of autoimmune diseases, atherosclerosis, inflammatory disorders, cancer, diabetic retinopathy, diabetes, osteoporosis and viral infections.
Researchers have compared the cellular responses driving allergic asthma to those in individuals with allergic rhinitis and conjunctivitis but no allergic response in the lungs. Asthma is “an umbrella term,” Josalyn Cho told BioWorld. But under that umbrella, the largest group of people are those whose asthma begins in childhood. And “those folks almost exclusively develop their asthma after they develop allergies.”
With much-awaited readouts from their broad oncology-focused collaboration due later this year, Arcus Biosciences Inc. and Gilead Sciences Inc. have decided to expand efforts into the inflammatory disease space via an early stage research agreement that could be worth as much as $1 billion. Terms include a $35 million up-front payment to Arcus, which is making its first move beyond oncology.
RSS
